Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
about
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsClinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsA review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway.miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma.PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy
P2860
Q33761531-01B77D11-3EED-4BEF-BD66-12A8C26FB52DQ33889152-6E100E08-AA82-41DE-8D01-98793B4BB10BQ37342909-DBC7B3BE-6C5A-4282-B808-7566E58F1DDDQ37619959-BDC4EA8A-2D91-4060-8C43-E8FA9C5A51DDQ37665702-A82A637E-1742-47DD-B516-FC49BDCA1C1AQ38614928-43D64C4C-534C-4E87-82A9-BBCAC6761F3BQ39401628-0DE539CD-DE84-453E-B2EA-8D453EDC7C82Q41080796-D3076893-F2F9-4B3A-B0F2-479FE2C6D283Q41975973-88C6673C-0202-4760-BD45-62393F92C366Q44727423-2FA30EA8-DB8B-4038-81A5-94A9C723189CQ47694209-83679D14-A2E2-4560-9A0C-9BA5B6CE807FQ47701410-DD00D197-15E2-46B4-9EDD-49C4385DB61FQ50067454-915D260E-8B11-428A-A1B2-FD817D0FF689Q52657087-0BBA29FC-91FF-4872-A42C-24A3043B1304Q58803894-3FF04B59-0C97-4B0F-AC9B-242CAB5E9200
P2860
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Personalized comprehensive mol ...... tations for precision medicine
@ast
Personalized comprehensive mol ...... tations for precision medicine
@en
type
label
Personalized comprehensive mol ...... tations for precision medicine
@ast
Personalized comprehensive mol ...... tations for precision medicine
@en
prefLabel
Personalized comprehensive mol ...... tations for precision medicine
@ast
Personalized comprehensive mol ...... tations for precision medicine
@en
P2093
P2860
P356
P1433
P1476
Personalized comprehensive mol ...... tations for precision medicine
@en
P2093
Eswaran Devarajan
Mary F McGuire
Michael J Wagner
Nawid M Sarwari
Pete Anderson
Robert E Brown
Shanon Westin
Shumei Kato
Valerae O Lewis
Vivek Subbiah
P2860
P304
40642-40654
P356
10.18632/ONCOTARGET.5841
P407
P577
2015-10-15T00:00:00Z